Ma J, Liu L Y, Wu P H, Liao Y, Tao T, Liu W
Department of Endocrinology and Metabolism, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Shanghai 200127, China.
Department of Endocrinology and Metabolism, Shanghai Gongli Hospital, Shanghai, China.
J Diabetes Res. 2014;2014:294017. doi: 10.1155/2014/294017. Epub 2014 Mar 4.
This study was designed to compare the effects of metformin and repaglinide on the fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) in newly diagnosed type 2 diabetes in China.
A total of 107 newly diagnosed type 2 diabetic patients (46 women and 61 men) participated in the study. All patients received 3-month treatment of metformin or repaglinide. Fasting blood glucose and HbA1c were determined at baseline and at the end of the 3-month of treatment.
FPG and HbA1c decreased in both metformin and repaglinide groups after 3 months treatment (P < 0.01). The reduction of HbA1c was significantly greater in the repaglinide group (P < 0.01). Metformin decreases fasting insulin concentration and HOMA-IR (P < 0.01), and repaglinide improves HOMA-β(P < 0.01). Triglycerides (TG) were reduced in both groups (P < 0.01 in metformin group; P < 0.05 in repaglinide group), but total cholesterol (TC) and low-density lipoprotein (LDL) were decreased only after metformin treatment (P < 0.05).
Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China. Repaglinide had no effect on insulin sensitivity, but it improved β-cell function.
本研究旨在比较二甲双胍和瑞格列奈对中国新诊断2型糖尿病患者空腹血糖（FPG）和糖化血红蛋白（HbA1c）的影响。
共有107例新诊断的2型糖尿病患者（46例女性和61例男性）参与本研究。所有患者接受为期3个月的二甲双胍或瑞格列奈治疗。在基线及治疗3个月末测定空腹血糖和HbA1c。
治疗3个月后，二甲双胍组和瑞格列奈组的FPG和HbA1c均下降（P<0.01）。瑞格列奈组HbA1c的降低幅度显著更大（P<0.01）。二甲双胍可降低空腹胰岛素浓度和HOMA-IR（P<0.01），瑞格列奈可改善HOMA-β（P<0.01）。两组的甘油三酯（TG）均降低（二甲双胍组P<0.01；瑞格列奈组P<0.05），但仅在二甲双胍治疗后总胆固醇（TC）和低密度脂蛋白（LDL）降低（P<0.05）。
在中国新诊断的2型糖尿病患者中，瑞格列奈和二甲双胍在血糖控制方面均有效。瑞格列奈对胰岛素敏感性无影响，但可改善β细胞功能。
